- Oxford Biomedica PLC oxford Biomedica to host webinar showcasing the TetraVectaTM system TranscriptOct 02, 2023
- Half Year 2023 Oxford Biomedica PLC Earnings Call TranscriptSep 20, 2023£2.69 (+11.39%)Earnings
- Full Year 2022 Oxford Biomedica PLC Earnings Call TranscriptApr 25, 2023£4.53 (+0.67%)Earnings
- Oxford Biomedica PLC at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Half Year 2022 Oxford BioMedica PLC Earnings Call TranscriptSep 15, 2022£4.4 (-3.93%)Earnings
- Full Year 2021 Oxford BioMedica PLC Earnings Call TranscriptApr 20, 2022£5.45 (-14.71%)Earnings
- Half Year 2021 Oxford BioMedica PLC Earnings Call TranscriptSep 22, 2021£16.34 (+10.55%)Earnings
- Full Year 2020 Oxford BioMedica PLC Earnings Call TranscriptApr 15, 2021£10.42 (+0.19%)Earnings
- Half Year 2020 Oxford BioMedica PLC Earnings Call TranscriptSep 17, 2020£8.47 (+1.44%)Earnings
- Oxford BioMedica PLC Annual Shareholders Meeting TranscriptJun 23, 2020
- Full Year 2019 Oxford BioMedica PLC Earnings Call TranscriptMay 06, 2020£7.07 (-2.75%)Earnings
- Half Year 2019 Oxford BioMedica PLC Earnings Call TranscriptSep 04, 2019£6.4 (+0.16%)Earnings
- Full Year 2018 Oxford BioMedica PLC Earnings Call TranscriptMar 14, 2019£6.5 (-2.26%)Earnings
Oxford Biomedica PLC at JPMorgan Healthcare Conference Transcript
Good afternoon, everyone. My name is Jem de los Santos, I'm a Vice President in JPMorgan's Healthcare Investment Banking team based in London. Very happy to present Oxford Biomedica. And without further ado, I'll hand it over to Stuart Paynter, the CFO.
Thank you very much, and good afternoon to everyone. Thank you for attending on the graveyard shift on a Wednesday afternoon. It's been a really nice conference, and thank you for JPMorgan for hosting and letting us tell our story. So Oxford Biomedica, we're a focused cell and gene therapy CDMO. We've been on this journey from becoming a product company to an innovation at CDMO for a while now. And that journey is now complete. I'm going to take you through the story, a little bit of history and how we're positioned to really make a big splash in the cell and gene therapy market and where we see some of the opportunities for growth. So there are going to be some forward-looking statements.
So here's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)